FATE
Price
$2.31
Change
-$0.02 (-0.86%)
Updated
Sep 11 closing price
Capitalization
276.79M
47 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$2.91
Change
+$0.10 (+3.56%)
Updated
Sep 11 closing price
Capitalization
208.43M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs NKTX

FATE vs NKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FATE vs. NKTX commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and NKTX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($277M) has a higher market cap than NKTX($208M). FATE YTD gains are higher at: 135.091 vs. NKTX (57.297). FATE (-121.6M) and NKTX (-122.62M) have comparable annual earnings (EBITDA) . NKTX has more cash in the bank: 183M vs. FATE (154M). NKTX (73.5M) and FATE (75.7M) have identical debt. FATE has higher revenues than NKTX: FATE (6.49M) vs NKTX (0).
FATENKTXFATE / NKTX
Capitalization277M208M133%
EBITDA-121.6M-122.62M99%
Gain YTD135.09157.297236%
P/E RatioN/AN/A-
Revenue6.49M0-
Total Cash154M183M84%
Total Debt75.7M73.5M103%
FUNDAMENTALS RATINGS
FATE vs NKTX: Fundamental Ratings
FATE
NKTX
OUTLOOK RATING
1..100
8138
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
10
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3639
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (10) in the null industry is in the same range as FATE (26) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.

NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.

NKTX's SMR Rating (97) in the null industry is in the same range as FATE (98) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.

FATE's Price Growth Rating (36) in the Biotechnology industry is in the same range as NKTX (39) in the null industry. This means that FATE’s stock grew similarly to NKTX’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NKTX (100) in the null industry. This means that FATE’s stock grew similarly to NKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATENKTX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (FATE: $2.31 vs. NKTX: $2.91)
Brand notoriety: FATE and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 44% vs. NKTX: 74%
Market capitalization -- FATE: $276.79M vs. NKTX: $208.43M
FATE [@Biotechnology] is valued at $276.79M. NKTX’s [@Biotechnology] market capitalization is $208.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and NKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while NKTX’s TA Score has 6 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 5 bearish.
  • NKTX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NKTX is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -6.85% price change this week, while NKTX (@Biotechnology) price change was -0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

FATE is expected to report earnings on Oct 29, 2026.

NKTX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
FATE
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBPTX62.660.39
+0.63%
Neuberger Large Cap Value Tr
IJSAX11.78N/A
N/A
VY® JPMorgan Small Cap Core Equity A
PGRTX17.58N/A
N/A
Principal SmallCap Growth I Instl
RMQHX648.19N/A
N/A
Rydex Monthly Rbl NASDAQ-100® 2x Strt H
IEQAX20.56-0.01
-0.05%
ICON Equity Income Investor